These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 39161530)

  • 1. Unraveling the Complexities of Idiopathic Multicentric Castleman Disease and Its Multi-systemic Associations: A Case Report.
    Palvia AR; Saha P; Nandi AR; Damera AR; Suresh A
    Cureus; 2024 Jul; 16(7):e64935. PubMed ID: 39161530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
    Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
    Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
    Lang E; Sande B; Brodkin S; van Rhee F
    Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
    Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
    Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multicentric Castlemans disease. Symptoms, diagnostics and therapy].
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
    Bedier H; Isnard S; Maedler-Kron C; Routy JP
    Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
    Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
    PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Castleman Disease.
    Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
    Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
    Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
    J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of siltuximab in the treatment of multicentric Castleman's disease.
    Sarosiek S; Shah R; Munshi NC
    Ther Adv Hematol; 2016 Dec; 7(6):360-366. PubMed ID: 27904739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report.
    Strach M; Kuszmiersz P; Chmura Ł; Korkosz M
    Clin Case Rep; 2023 Oct; 11(10):e7981. PubMed ID: 37854256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are Patients with HHV-8 Associated Castleman Disease Successfully Treated with Rituximab at Risk of Subsequently Developing HHV-8 Negative (Idiopathic) Castleman Disease?
    Ha G; Kwong K; Tanaka B; Nishimura Y; Chong C
    Eur J Case Rep Intern Med; 2023; 10(7):003904. PubMed ID: 37455698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of Castleman's disease with siltuximab - case report and review of literature.
    Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
    Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
    Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
    Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease.
    Kawanishi M; Kamei F; Sonoda H; Oba M; Fukunaga S; Egawa M; Koyama T; Sato Y; Tanabe K; Ito T
    CEN Case Rep; 2023 May; 12(2):242-248. PubMed ID: 36414812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Unicentric Castlemans disease. Symptoms, diagnostics and therapy].
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2021; 67(8):465-473. PubMed ID: 35459366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoids combined with tofacitinib in the treatment of Castleman's disease: A case report.
    Liu XR; Tian M
    World J Clin Cases; 2022 Oct; 10(29):10794-10802. PubMed ID: 36312499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease.
    Van Nieuwenhove E; Humblet-Baron S; Van Eyck L; De Somer L; Dooley J; Tousseyn T; Hershfield M; Liston A; Wouters C
    Pediatrics; 2018 Sep; 142(3):. PubMed ID: 30139808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.